Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 15;24(14):11495.
doi: 10.3390/ijms241411495.

Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer

Brigida Stanzione  1 , Alessandro Del Conte  1 , Elisa Bertoli  1   2 , Elisa De Carlo  1 , Alberto Revelant  3 , Michele Spina  1 , Alessandra Bearz  1
Affiliations
Review

Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer

Brigida Stanzione et al. Int J Mol Sci. .

Abstract

ROS proto-oncogene 1 (ROS1) rearrangements occur in 0.9-2.6% of patients with non small cell lung cancer (NSCLC), conferring sensitivity to treatment with specific tyrosine-kinase inhibitors (TKI). Crizotinib, a first-generation TKI, was the first target-therapy approved for the first-line treatment of ROS1-positive NSCLC. Recently, entrectinib, a multitarget inhibitor with an anti-ROS1 activity 40 times more potent than crizotinib and better activity on the central nervous system (CNS), received approval for treatment-naive patients. After a median time-to-progression of 5.5-20 months, resistance mechanisms can occur, leading to tumor progression. Therefore, newer generation TKI with greater potency and brain penetration have been developed and are currently under investigation. This review summarizes the current knowledge on clinicopathological characteristics of ROS1-positive NSCLC and its therapeutic options.

Keywords: ROS1; non small cell lung cancer; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline of main findings in ROS1-positive NSCLC.
See this image and copyright information in PMC

References

    1. Siegel R., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Pikor L.A., Ramnarine V.R., Lam S., Lam W.L. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82:179–189. doi: 10.1016/j.lungcan.2013.07.025. - DOI - PubMed
    1. Acquaviva J., Wong R., Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim. Biophys. Acta. 2009;1795:37–52. doi: 10.1016/j.bbcan.2008.07.006. - DOI - PubMed
    1. Davies K.D., Doebele R.C. Molecular Pathways: ROS1 Fusion Proteins in Cancer. Clin. Cancer Res. 2013;19:4040–4045. doi: 10.1158/1078-0432.CCR-12-2851. - DOI - PMC - PubMed
    1. Charest A., Wilker E.W., McLaughlin M.E., Lane K., Gowda R., Coven S., McMahon K., Kovach S., Feng Y., Yaffe M.B., et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glio-blastoma in mice. Cancer Res. 2006;66:7473–7481. doi: 10.1158/0008-5472.CAN-06-1193. - DOI - PubMed

MeSH terms